Nicholas James Hornstein, MD, PhD

Data from the GALAXY study in Japan may inform future use of total neoadjuvant therapy among patients with rectal cancer in the US.

Bodies like the NCCN must keep up with data related to ctDNA so that it can be incorporated in a measured manner, said Nicholas Hornstein, MD, PhD.

Circulating tumor DNA may particularly help adjuvant treatment decision-making in stage II colon cancer, according to Nicholas Hornstein, MD, PhD.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

The most common toxicity associated with TAS-102 was neutropenia, with grade 3 events occurring in 73.3% of patients with colorectal cancer.

“…I like TAS-102 as an agent, but we need better drugs than we have right now to clear ctDNA and cure patients,” said Hornstein, MD, PhD.

The phase 2 INTERCEPT-TT trial showed that TAS-102 induced ctDNA clearance following adjuvant chemotherapy in patients with colorectal cancer.

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

The CHALLENGE trial in CRC studied structured exercise and demonstrated a DFS benefit comparable to or exceeding oxaliplatin chemotherapy.